newsfilter
← Latest News
GlobeNewswire·

Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates

Updated Preliminary Clinical Data Presented for Lead Drug Candidate Repotrectinib and Elzovantinib at the AACR-NCI-EORTC Conference Multiple FDA Interactions Anticipated in Q4 2021 and 1H 2022 for Repotrectinib and Elzovantinib Cash, Cash Equivalents,